The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
COPD Drugs-Global Market Insights and Sales Trends 2024
Synopsis
COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors， steroids, combination therapies, etc.
The global COPD Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of COPD Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling COPD Drugs market. Bronchodilators, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the PDE-4 Inhibitors segment is estimated at % CAGR for the next seven-year period.
One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for COPD Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global COPD Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global COPD Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, COPD Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of COPD Drugs covered in this report include Pfizer, Novartis, GlaxoSmithKline, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG and Teva Pharmaceutical Industries, etc.
The global COPD Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
GlaxoSmithKline
Merck
Abbott Laboratories
Boehringer Ingelheim
AstraZeneca
Roche Holding AG
Teva Pharmaceutical Industries
Vectura Group
Mylan NV
Global COPD Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global COPD Drugs market, Segment by Type:
Bronchodilators
PDE-4 Inhibitors
Steroids
Combination Therapies
Others
Global COPD Drugs market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of COPD Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors， steroids, combination therapies, etc.
The global COPD Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of COPD Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling COPD Drugs market. Bronchodilators, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the PDE-4 Inhibitors segment is estimated at % CAGR for the next seven-year period.
One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for COPD Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global COPD Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global COPD Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, COPD Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of COPD Drugs covered in this report include Pfizer, Novartis, GlaxoSmithKline, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG and Teva Pharmaceutical Industries, etc.
The global COPD Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
GlaxoSmithKline
Merck
Abbott Laboratories
Boehringer Ingelheim
AstraZeneca
Roche Holding AG
Teva Pharmaceutical Industries
Vectura Group
Mylan NV
Global COPD Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global COPD Drugs market, Segment by Type:
Bronchodilators
PDE-4 Inhibitors
Steroids
Combination Therapies
Others
Global COPD Drugs market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of COPD Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of COPD Drugs
1.1 COPD Drugs Market Overview
1.1.1 COPD Drugs Product Scope
1.1.2 COPD Drugs Market Status and Outlook
1.2 Global COPD Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global COPD Drugs Market Size by Region (2018-2029)
1.4 Global COPD Drugs Historic Market Size by Region (2018-2023)
1.5 Global COPD Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, COPD Drugs Market Size (2018-2029)
1.6.1 North America COPD Drugs Market Size (2018-2029)
1.6.2 Europe COPD Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific COPD Drugs Market Size (2018-2029)
1.6.4 Latin America COPD Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa COPD Drugs Market Size (2018-2029)
2 COPD Drugs Market by Type
2.1 Introduction
2.1.1 Bronchodilators
2.1.2 PDE-4 Inhibitors
2.1.3 Steroids
2.1.4 Combination Therapies
2.1.5 Others
2.2 Global COPD Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global COPD Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global COPD Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America COPD Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe COPD Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific COPD Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America COPD Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa COPD Drugs Revenue Breakdown by Type (2018-2029)
3 COPD Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global COPD Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global COPD Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global COPD Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America COPD Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe COPD Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific COPD Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America COPD Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa COPD Drugs Revenue Breakdown by Application (2018-2029)
4 COPD Drugs Competition Analysis by Players
4.1 Global COPD Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in COPD Drugs as of 2022)
4.3 Date of Key Players Enter into COPD Drugs Market
4.4 Global Top Players COPD Drugs Headquarters and Area Served
4.5 Key Players COPD Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 COPD Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer COPD Drugs Products, Services and Solutions
5.1.4 Pfizer COPD Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis COPD Drugs Products, Services and Solutions
5.2.4 Novartis COPD Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 GlaxoSmithKline
5.3.1 GlaxoSmithKline Profile
5.3.2 GlaxoSmithKline Main Business
5.3.3 GlaxoSmithKline COPD Drugs Products, Services and Solutions
5.3.4 GlaxoSmithKline COPD Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Merck Recent Developments
5.4 Merck
5.4.1 Merck Profile
5.4.2 Merck Main Business
5.4.3 Merck COPD Drugs Products, Services and Solutions
5.4.4 Merck COPD Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Merck Recent Developments
5.5 Abbott Laboratories
5.5.1 Abbott Laboratories Profile
5.5.2 Abbott Laboratories Main Business
5.5.3 Abbott Laboratories COPD Drugs Products, Services and Solutions
5.5.4 Abbott Laboratories COPD Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Abbott Laboratories Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim COPD Drugs Products, Services and Solutions
5.6.4 Boehringer Ingelheim COPD Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 AstraZeneca
5.7.1 AstraZeneca Profile
5.7.2 AstraZeneca Main Business
5.7.3 AstraZeneca COPD Drugs Products, Services and Solutions
5.7.4 AstraZeneca COPD Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 AstraZeneca Recent Developments
5.8 Roche Holding AG
5.8.1 Roche Holding AG Profile
5.8.2 Roche Holding AG Main Business
5.8.3 Roche Holding AG COPD Drugs Products, Services and Solutions
5.8.4 Roche Holding AG COPD Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Roche Holding AG Recent Developments
5.9 Teva Pharmaceutical Industries
5.9.1 Teva Pharmaceutical Industries Profile
5.9.2 Teva Pharmaceutical Industries Main Business
5.9.3 Teva Pharmaceutical Industries COPD Drugs Products, Services and Solutions
5.9.4 Teva Pharmaceutical Industries COPD Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Teva Pharmaceutical Industries Recent Developments
5.10 Vectura Group
5.10.1 Vectura Group Profile
5.10.2 Vectura Group Main Business
5.10.3 Vectura Group COPD Drugs Products, Services and Solutions
5.10.4 Vectura Group COPD Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Vectura Group Recent Developments
5.11 Mylan NV
5.11.1 Mylan NV Profile
5.11.2 Mylan NV Main Business
5.11.3 Mylan NV COPD Drugs Products, Services and Solutions
5.11.4 Mylan NV COPD Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Mylan NV Recent Developments
6 North America
6.1 North America COPD Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe COPD Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific COPD Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America COPD Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa COPD Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 COPD Drugs Market Dynamics
11.1 COPD Drugs Industry Trends
11.2 COPD Drugs Market Drivers
11.3 COPD Drugs Market Challenges
11.4 COPD Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
